Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 9 July 2009, Vol. 114, No. 2, pp. 357-359.
Prepublished online as a Blood First Edition Paper on March 16, 2009; DOI 10.1182/blood-2008-09-177360.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Table and Figure
Right arrow All Versions of this Article:
blood-2008-09-177360v1
114/2/357    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kryczek, I.
Right arrow Articles by Zou, W.
Related Collections
Right arrow Immunobiology
Right arrow Brief Reports
Right arrowRelated Article in Blood Online
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

IMMUNOBIOLOGY

Brief report

Endogenous IL-17 contributes to reduced tumor growth and metastasis

Ilona Kryczek1, Shuang Wei1, Wojciech Szeliga1, Linhua Vatan1, and Weiping Zou1

1 Department of Surgery, University of Michigan, Ann Arbor

It has been reported that ectopically expressed interleukin-17 (IL-17) in tumor cells suppresses tumor progression through enhanced antitumor immunity in immune competent mice or promote tumor progression through an increase in inflammatory angiogenesis in immune-deficient mice. The role of endogenous IL-17 in tumor immunity remains undefined. Here we showed that tumor growth and lung metastasis were enhanced in IL-17–deficient mice, associated with decreased interferon-{gamma}+ natural killer cells and tumor specific interferon-{gamma}+ T cells in the tumor draining lymph nodes and tumors. Together with the published data showing that in vitro transforming growth factor-β and IL-6–polarized Th17 cells induce tumor regression, our work supports the notion that endogenous IL-17 or/and Th17 cells may play a protective role in tumor immunity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Does IL-17 promote tumor growth?
Pawel Muranski and Nicholas P. Restifo
Blood 2009 114: 231-232. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
G. Murugaiyan and B. Saha
Protumor vs Antitumor Functions of IL-17
J. Immunol., October 1, 2009; 183(7): 4169 - 4175.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. Kryczek, M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T. H. Welling, et al.
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
Blood, August 6, 2009; 114(6): 1141 - 1149.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Muranski and N. P. Restifo
Does IL-17 promote tumor growth?
Blood, July 9, 2009; 114(2): 231 - 232.
[Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020